On the 18th August 2015, the Expert Committee of the US American Food and Drug Administration (FDA) spoke up for the approval of the medicine Flibanserin, which is in the meantime generally known under the name of Pink Viagra. The contribution sheds light on cultural norms and socio-sexual standards which possibly restricting female sexual pleasure and discusses the risks of introducing a "female desire pill" by providing a critical examination of traditional sexual scripts and associated gender roles as well as its associations with sexuality-related outcomes. Finally, the authors plead for prioritizing the development in the area of sex research of concepts which enhance sexual pleasure for both genders rather than bringing a medicine onto the market that can affect biochemical processes in the brain and result in a series of side effects despite insufficient empirical evidence of effectiveness.